{"id":1458,"date":"2001-08-01T12:03:00","date_gmt":"2001-08-01T10:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/praevention-des-ploetzlichen-herztods-medikamentoese-und-nicht-medikamentoese-antiarrhythmische-therapie"},"modified":"2001-08-01T12:03:00","modified_gmt":"2001-08-01T10:03:00","slug":"praevention-des-ploetzlichen-herztods-medikamentoese-und-nicht-medikamentoese-antiarrhythmische-therapie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/praevention-des-ploetzlichen-herztods-medikamentoese-und-nicht-medikamentoese-antiarrhythmische-therapie","title":{"rendered":"Pr\u00e4vention des Pl\u00f6tzlichen Herztods. Medikament\u00f6se und nicht-medikament\u00f6se antiarrhythmische Therapie"},"content":{"rendered":"<p>Zusammenfassung: Patienten nach Myokardinfarkt sowie Patienten mit Herzinsuffizienz sollten zur Pr\u00e4vention des Pl\u00f6tzlichen Herztods Betarezeptoren-Blocker erhalten. Klasse-I-Antiarrhythmika sind bei beiden Patientengruppen kontraindiziert. Sotalol hat ein hohes proarrhythmisches Potential und verbessert die Prognose nicht. Amiodaron verbessert die Prognose allenfalls geringf\u00fcgig, wobei ein g\u00fcnstiger Effekt am ehesten noch bei Patienten mit hochgradig eingeschr\u00e4nkter linksventrikul\u00e4rer Funktion und nicht-isch\u00e4mischer [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Patienten nach Myokardinfarkt sowie Patienten mit Herzinsuffizienz sollten zur Pr\u00e4vention des Pl\u00f6tzlichen Herztods Betarezeptoren-Blocker erhalten. Klasse-I-Antiarrhythmika sind bei beiden Patientengruppen kontraindiziert. Sotalol hat ein hohes proarrhythmisches Potential und verbessert die Prognose nicht. Amiodaron verbessert die Prognose allenfalls geringf\u00fcgig, wobei ein g\u00fcnstiger Effekt am ehesten noch bei Patienten mit hochgradig eingeschr\u00e4nkter linksventrikul\u00e4rer Funktion und nicht-isch\u00e4mischer [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1797,127,3478,126,1798,1799,2525,129,128,131,1635,3483,2524,1796,251,1639,3480,3482,1005,3481,2275,2109,2526,252,3479,1421,3487,71,180,187,1800,1803,1801,203,1802,2276,633,3485,3484,65,3486,1804,183,574,1418,1794],"class_list":["post-1458","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-aicd","tag-amiodaron","tag-amiovirt-studie","tag-antiarrhythmika","tag-automatischer-implantierbarer-kardioverter-defibrillator","tag-avid-studie","tag-best-studie","tag-beta-blocker","tag-betablocker","tag-betarezeptoren-blocker","tag-bisoprolol","tag-bradykardie","tag-bucindolol","tag-cabg-patch-studie","tag-camiat-studie","tag-carvedilol","tag-cash-studie","tag-cast-studien","tag-cat-studie","tag-chf-stat-studie","tag-cibis-ii-studie","tag-cids-studie","tag-copernicus-studie","tag-emiat-studie","tag-encainid","tag-flecainid","tag-gesica-studie","tag-herzinfarkt","tag-herzinsuffizienz","tag-herzrhythmusstoerungen","tag-icd","tag-implantate","tag-implantierbarer-defibrillator","tag-kammerflimmern","tag-madit-studie","tag-merit-hf-studie","tag-metoprolol","tag-moricizin","tag-mustt-studie","tag-myokardinfarkt","tag-oxprenolol","tag-ploetzlicher-herztod","tag-rhythmusstoerungen","tag-sotalol","tag-sword-studie","tag-tachykardien"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1458"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1458\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}